1. "Elsevier Inc."
Formats
  1. Journal Article (7386)
  2. Meeting Abstract (4694)
  3. Review (617)
  4. Book Section (538)
  5. Editorial (250)
  6. Conference Paper (138)
  7. Correspondence (92)
  8. Guidelines (82)
  9. Research Letter (29)
  10. Miscellaneous (15)
  11. Book Whole (14)
Groups
  1. Department of Medicine (4610)
  2. Surgery (3546)
  3. Survivorship Research (2658)
  4. Solid Tumor Oncology Division (2651)
  5. Radiation Oncology, Department of (2158)
  6. GSK Faculty (1937)

More Groups

People
  1. Nadeem Abu-Rustum (464)
  2. Dennis Chi (420)
  3. Nancy Lee (409)
  4. Michael Zelefsky (401)
  5. Sergio Giralt (384)
  6. John Mulhall (377)

More People

Years
  1. 2025 (240)
  2. 2024 (784)
  3. 2023 (762)
  4. 2022 (794)
  5. 2021 (723)
  6. 2020 (714)

More Years

Publications
  1. International Journal of Radiation Oncology, Biology, Physics (2610)
  2. Gynecologic Oncology (1197)
  3. Journal of Thoracic Oncology (967)
  4. Biology of Blood and Marrow Transplantation (815)
  5. European Journal of Cancer (524)
  6. Journal of Sexual Medicine (435)

More Publications

Publishers
  1. Elsevier Inc. (13855)

Results (13855)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • First-line monotherapy with nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and correlation of outcomes with PD-L1 status
    Meeting Abstract

    Rizvi, N. A.; Shepherd, F. A.; Antonia, S. J.; Brahmer, J. R.; Chow, L. Q.; Goldman, J.; Juergens, R.; Borghaei, H.; Ready, N. E.; Gerber, D. E.; more...
    International Journal of Radiation Oncology, Biology, Physics (2014)

    Fulltext@MSK | Save
  • Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) maintenance as monotherapy or in combination with bevacizumab (BEV) for non-small cell lung cancer (NSCLC) previously treated with chemotherapy
    Meeting Abstract

    Rizvi, N. A.; Antonia, S. J.; Shepherd, F. A.; Chow, L. Q.; Goldman, J.; Shen, Y.; Chen, A. C.; Gettinger, S.
    International Journal of Radiation Oncology, Biology, Physics (2014)

    Fulltext@MSK | Save
  • Stage III non-small cell lung cancer treated without concurrent chemotherapy: What is the optimal radiation dose?
    Meeting Abstract

    Rimner, A.; Din, S.; Shaikh, F.; Foster, A.; Tyagi, N.; Abi Aad, S.; Paik, P.; Yorke, E. D.; Chaft, J. E.; Gelblum, D. Y.; more...
    International Journal of Radiation Oncology, Biology, Physics (2014)

    Fulltext@MSK | Save
  • Phase II study of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced, refractory squamous non-small cell lung cancer
    Meeting Abstract

    Ramalingam, S. S.; Mazieres, J.; Planchard, D.; Stinchcombe, T. E.; Dy, G. K.; Antonia, S. J.; Horn, L.; Lena, H.; Minenza, E.; Mennecier, B.; more...
    International Journal of Radiation Oncology, Biology, Physics (2014)

    Fulltext@MSK | Save
  • Pattern of failure in metastatic EGFR-mutant NSCLC treated with erlotinib: A role for upfront radiation therapy?
    Meeting Abstract

    Patel, S.; Rimner, A.; Foster, A.; Zhang, Z.; Woo, K. M.; Yu, H. A.; Riely, G. J.; Wu, A. J.
    International Journal of Radiation Oncology, Biology, Physics (2014)

    Fulltext@MSK | Save
  • Risk of brain metastasis in EGFR-mutant NSCLC treated with erlotinib: A role for prophylactic cranial irradiation?
    Meeting Abstract

    Patel, S.; Rimner, A.; Foster, A.; Zhang, Z.; Woo, K. M.; Yu, H. A.; Riely, G. J.; Wu, A. J.
    International Journal of Radiation Oncology, Biology, Physics (2014)

    Fulltext@MSK | Save
  • EGFR exon 20 alterations in lung adenocarcinomas and their impact on overall survival and response to EGFR TKI
    Meeting Abstract

    Naidoo, J.; Sima, C. S.; Rodriguez, K.; Busby, N.; Arcila, M. E.; Yu, H. A.
    International Journal of Radiation Oncology, Biology, Physics (2014)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes for 61 patients with metastatic pulmonary carcinoids
    Meeting Abstract

    Litvak, A. M.; Iyriboz, T.; Zakowski, M.; Woo, K.; Krug, L.; Rudin, C.; Pietanza, C.
    International Journal of Radiation Oncology, Biology, Physics (2014)

    Fulltext@MSK | Save
  • Efficacy and safety of ceritinib in patients with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): An update of ASCEND-1
    Meeting Abstract

    Kim, D.; Mehra, R.; Tan, D. S. W.; Felip, E.; Chow, L. Q. M.; Camidge, D. R.; Vansteenkiste, J.; Sharma, S.; De Pas, T.; Riely, G. J.; more...
    International Journal of Radiation Oncology, Biology, Physics (2014)

    Fulltext@MSK | Save
  • Continued afatinib (A) with the addition of cetuximab (C) after progression on afatinib in patients with acquired resistance (AR) to gefitinib (G) or erlotinib (E)
    Meeting Abstract

    Horn, L.; Gettinger, S.; Camidge, R.; Smit, E.; Janjigian, Y.; Pao, W.; Schnell, D.; Wang, B.; Chand, V.; Groen, H.
    International Journal of Radiation Oncology, Biology, Physics (2014)

    Fulltext@MSK | Save